Trial · NCT01126255
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Score of the characteristics of Lichen sclerosus based on vulvar efflorescences | at 12 weeks | The severity of the Lichen sclerosus will be assessed by a metric score, which is based on 6 items (abrasion, hyperkeratosis, rhagades, synechia, sclerosis, atrophy of labia/clitoris) consisting of three levels (0=no signs, 1=few signs, 2=pronounced signs). |
| Secondary | Patient-reported symptoms | at baseline | The patient will report the following symptoms on a scale from 0 to 10 pruritus, burning or pain, sore. |
| Secondary | Quality of life | at baseline | The patient will report quality of life on the SF12 questionnaire. |
| Secondary | Adverse events | at baseline | The tolerability of the topical treatment will be assessed by all adverse events occuring at the site of application. |
| Secondary | Patient-reported symptoms | at 6 weeks | The patient will report the following symptoms on a scale from 0 to 10: pruritus, burning or pain, sore. |
| Secondary | Patient-reported symptoms | at 12 weeks | The patient will report the following symptoms on a scale from 0 to 10: pruritus, burning or pain, sore. |
| Secondary | Patient-reported symptoms | at 18 weeks | The patient will report the following symptoms on a scale from 0 to 10 pruritus, burning or pain, sore. |
| Secondary | Patient-reported symptoms | at 24 weeks | The patient will report the following symptoms on a scale from 0 to 10 pruritus, burning or pain, sore. |
| Secondary | Quality of life | at 12 weeks | The patient will report quality of life on the SF12 questionnaire. |
| Secondary | Quality of life | at 24 weeks | The patient will report quality of life on the SF12 questionnaire. |
| Secondary | Adverse events | at 6 weeks | The tolerability of the topical treatment will be assessed by all adverse events occuring at the site of application. |
| Secondary | Adverse events | at 12 weeks | The tolerability of the topical treatment will be assessed by all adverse events occuring at the site of application. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01126255/registered